In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens
- PMID: 29633177
- PMCID: PMC5986684
- DOI: 10.1007/s40121-018-0200-7
In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens
Abstract
Introduction: Recent virus epidemics and rising antibiotic resistance highlight the importance of hygiene measures to prevent and control outbreaks. We investigated the in vitro bactericidal and virucidal efficacy of povidone-iodine (PVP-I) 7% gargle/mouthwash at defined dilution against oral and respiratory tract pathogens.
Methods: PVP-I was tested against Klebsiella pneumoniae and Streptococcus pneumoniae according to bactericidal quantitative suspension test EN13727 and against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses (SARS-CoV and MERS-CoV), rotavirus strain Wa and influenza virus A subtype H1N1 according to virucidal quantitative suspension test EN14476. PVP-I 7% gargle/mouthwash was diluted 1:30 with water to a concentration of 0.23% (the recommended concentration for "real-life" use in Japan) and tested at room temperature under clean conditions [0.3 g/l bovine serum albumin (BSA), viruses only] and dirty conditions (3.0 g/l BSA + 3.0 ml/l erythrocytes) as an interfering substance for defined contact times (minimum 15 s). Rotavirus was tested without protein load. A ≥ 5 log10 (99.999%) decrease of bacteria and ≥ 4 log10 (99.99%) reduction in viral titre represented effective bactericidal and virucidal activity, respectively, per European standards.
Results: PVP-I gargle/mouthwash diluted 1:30 (equivalent to a concentration of 0.23% PVP-I) showed effective bactericidal activity against Klebsiella pneumoniae and Streptococcus pneumoniae and rapidly inactivated SARS-CoV, MERS-CoV, influenza virus A (H1N1) and rotavirus after 15 s of exposure.
Conclusion: PVP-I 7% gargle/mouthwash showed rapid bactericidal activity and virucidal efficacy in vitro at a concentration of 0.23% PVP-I and may provide a protective oropharyngeal hygiene measure for individuals at high risk of exposure to oral and respiratory pathogens.
Funding: Mundipharma Research GmbH & Co. KG (MRG).
Keywords: Anti-infective agents; Local; Microbial sensitivity tests; Mouthwashes; Povidone-iodine; Respiratory tract infections.
References
-
- World Health Organization. Antibiotic resistance fact sheet. 2016. http://www.who.int/mediacentre/factsheets/antibiotic-resistance/en/. Accessed Mar 2018.
-
- Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2013. https://www.cdc.gov/drugresistance/threat-report-2013/. Accessed Mar 2018.
-
- World Health Organization. Resistant pneumococcal infections; the burden of disease and challenges in monitoring and controlling antimicrobial resistance. 2001. http://www.who.int/drugresistance/technicalguidance/en/resistantinfectio.... Accessed Mar 2018.
-
- World Health Organization. Influenza (seasonal) fact sheet. 2016. http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed Mar 2018.
-
- World Health Organization. Frequently asked questions on Middle East respiratory syndrome coronavirus (MERS-CoV). 2015. http://www.who.int/csr/disease/coronavirus_infections/faq/en/. Accessed Mar 2018.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous